Cover Image
市場調查報告書

週邊動脈疾病 (PAD):歐洲主要5國(5EU)的醫藥品市場預測與分析

Peripheral Artery Disease - 5EU Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 370551
出版日期 內容資訊 英文 272 Pages
訂單完成後即時交付
價格
Back to Top
週邊動脈疾病 (PAD):歐洲主要5國(5EU)的醫藥品市場預測與分析 Peripheral Artery Disease - 5EU Drug Forecast and Market Analysis to 2024
出版日期: 2015年10月01日 內容資訊: 英文 272 Pages
簡介

本報告提供歐洲的主要國家 (法國·德國·義大利·西班牙·英國) 的週邊動脈疾病 (以下簡稱PAD)治療藥臨床實驗趨勢與上市預測相關分析,提供您PAD概要 (病因·病理·症狀·診斷方法等) ,及目前的主要治療方法,現在臨床實驗中/已上市的開發中產品概要 (功效,SWOT分析及其它),市場規模預測 (總計11年份),主要的推動市場要素與其影響度等調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
  • 病期分類系統
  • 前兆·臨床症狀
  • 預後
  • 生活品質 (QoL)

第4章 疾病管理

  • 診斷·治療方法概要
    • 診斷
    • 治療指南有代表性的處方藥
  • 歐洲主要5個國家

第5章 競爭力的評估

  • 概要
  • 生活習慣的修正
    • 運動
    • 戒煙
  • 減輕風險要素的藥物
    • 降脂藥物
    • 抗高血壓藥物
    • 抗血栓藥
    • 降血糖藥
    • 血栓溶解藥
  • PAD症狀的治療藥:領導品牌
    • Pletal / Pletaal (cilostazol)
    • Praxilene (naftidrofuryl oxalate)
    • Trental (pentoxifylline)
    • 前列腺素和前列腺素類藥物療法
    • 其他藥物療法
  • 非藥物治療
    • 血運重建術

第6章 未滿足需求·市場機會分析

第7章 開發中產品的評估

  • 概要
  • 臨床實驗的後期階段產品潛力醫藥品
  • 臨床實驗的初期階段有潛力的醫藥品

第8章 市場未來展望

  • (EU5歐洲主要5個國家)
    • 預測
    • 近幾年主要的事件
    • 市場促進·阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC311CFR

In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

Total 5EU sales for the PAD therapeutics market in 2014 was approximately $198.8m. By 2024, sales of drugs that are used to relieve the symptoms of PAD will decline quite dramatically. This group of medicines will only contribute approximately 5% to total 5EU PAD sales by the end of the forecast period.

Scope

  • Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU PAD market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for PAD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification and Staging Systems
  • 3.3. Symptoms and Clinical Presentation
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Five Major European Markets

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Lifestyle Modifications
    • 5.2.1. Exercise
    • 5.2.2. Smoking cessation
  • 5.3. Risk Factor Modification Drugs
    • 5.3.1. Lipid-Lowering Medical Therapies
    • 5.3.2. Antihypertensive Medical Therapies
    • 5.3.3. Antithrombotic Medical Therapies
    • 5.3.4. Glucose-Lowering Medical Therapies
    • 5.3.5. Thrombolytic Therapies
  • 5.4. Medical Therapies Treating the Symptoms of PAD - Major Brands
    • 5.4.1. Pletal / Pletaal (cilostazol)
    • 5.4.2. Praxilene (naftidrofuryl oxalate)
    • 5.4.3. Trental (pentoxifylline)
    • 5.4.4. Prostaglandin and Prostanoid Medical Therapies
    • 5.4.5. Other Pharmacological Therapies
  • 5.5. Non-Pharmacological Therapies
    • 5.5.1. Revascularization

6. Unmet Need and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Late-Stage Clinical Development
    • 7.2.1. Xarelto (rivaroxaban)
    • 7.2.2. Brilinta (ticagrelor)
  • 7.3. Promising Drugs in Early-Stage Clinical Development
    • 7.3.1. Therapeutic Angiogenesis

8. Market Outlook

  • 8.1. Five Major European Markets
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed PAD Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Epidemiologist
    • 9.6.4. Global Head of Healthcare
    • 9.6.5. Global Director of Therapy Analysis and Epidemiology
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: The Various Causes of PAD
  • Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD
  • Table 3: The Various Etiologies of ALI
  • Table 4: The Symptoms of PAD
  • Table 5: Population Characteristics of Individuals who Require Regular Screening for PAD
  • Table 6: Treatment Guidelines for PAD
  • Table 7: 8MM, Most Prescribed Drugs for PAD by Class, 2015
  • Table 8: Country Profile - 5EU
  • Table 9: Leading Drugs for PAD Treatment, 2015
  • Table 10: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies
  • Table 11: Most Frequently Used Beta Blockers
  • Table 12: Product Profile - Beta Blockers
  • Table 13: Most Frequently Used ACE Inhibitors
  • Table 14: Product Profile - ACE Inhibitors
  • Table 15: Most Frequently Used ARBs
  • Table 16: Product Profile - ARBs
  • Table 17: Product Profile - Plavix (clopidogrel)
  • Table 18: Product Profile - Zontivity (vorapaxar)
  • Table 19: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study
  • Table 20: Product Profile - Metformin
  • Table 21: Product Profile - Pletal (cilostazol)
  • Table 22: Safety Profile - Pletal (cilostazol)
  • Table 23: SWOT Analysis of Pletal, 2015
  • Table 24: Global Sales Forecast ($m) for Cilostazol, 2014-2024
  • Table 25: Product Profile - Praxilene (naftidrofuryl)
  • Table 26: Safety Profile - Praxilene (naftidrofuryl)
  • Table 27: SWOT Analysis of Praxilene, 2015
  • Table 28: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024
  • Table 29: Product Profile - Trental (pentoxifylline)
  • Table 30: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol.
  • Table 31: The Incidence (%) of Side Effects with Trental
  • Table 32: SWOT Analysis of Trental, 2015
  • Table 33: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024
  • Table 34: Indications for Revascularization in PAD
  • Table 35: Major Unmet Needs and Opportunities in PAD
  • Table 36: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015
  • Table 37: Comparison of Therapeutic Classes in Development for PAD, 2015
  • Table 38: Product Profile - Xarelto (rivaroxaban)
  • Table 39: SWOT Analysis of Xarelto, 2015
  • Table 40: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024
  • Table 41: Product Profile - Brilinta (ticagrelor)
  • Table 42: Brilinta's Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study
  • Table 43: SWOT Analysis of Brilinta, 2015
  • Table 44: 8MM, Sales Forecast ($) for Brilinta, 2014-2024
  • Table 45: Sales Forecast ($m) for PAD in the 5EU, 2014-2024
  • Table 46: Key Events Impacting Sales for PAD in the 5EU, 2014-2024
  • Table 47: 5EU PAD Market - Drivers and Barriers, 2014-2024
  • Table 48: Abbreviations
  • Table 49: Key Launch Dates
  • Table 50: Key Patent Expiries
  • Table 51: High-Prescribing Physicians Non-KOLs Surveyed, By Country

List of Figures

  • Figure 1: Clinical Manifestations of PAD
  • Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis.
  • Figure 3: The Most Common Tests Used to Diagnose PAD in 5EU Patients, 2014
  • Figure 4: Breakdown of 5EU PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 5: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD
  • Figure 6: The Treatment Algorithm for IC Patients
  • Figure 7: The Treatment Algorithm for CLI Patients
  • Figure 8: The Treatment Algorithm for ALI Patients
  • Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024
  • Figure 10: Sales for PAD in the 5EU by Drug Class, 2014 and 2024
Back to Top